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HIV-Selectest is a serodiagnostic enzyme immunoassay (EIA), containing p6 and gp41 peptides, designed to
differentiate between vaccine-induced antibodies and true infections. A rapid test version of the HIV-Selectest
was developed. Both assays detected HIV antibodies in men and women within 2 to 4 weeks of infection, with
sensitivity similar to third-generation EIAs.
Most of the current HIV vaccine candidates contain multi-
ple viral components. As a result, many vaccine recipients react
positively in commercial diagnostic assays that detect HIV
antibodies, including enzyme immunoassays (EIAs), Western
blots (WB), and rapid tests. We have identified conserved
sequences in Env gp41 and Gag p6 which are not included in
most HIV vaccine candidates. A new HIV EIA termed HIV-
Selectest was developed, which distinguishes between vaccine-
induced antibodies and seroconversion due to true HIV infec-
tions (4, 5).
Before this assay can be implemented as part of the HIV
detection algorithm during HIV vaccine trials, it was important
to compare its sensitivity to those of currently available third-
generation EIAs and rapid tests. In addition, attention must be
given to detection of infections in women versus those in men,
since women may experience HIV/AIDS differently from men
(8, 10). We have recently developed a rapid test version of the
HIV-Selectest in order to facilitate point-of-care testing during
vaccine trials.
In the current studies, we evaluated serial samples obtained
from the following multiple cohorts of men and women from
the United States and Africa: plasma donors who acquired
HIV-1 in the United States (Center for HIV/AIDS Vaccine
Immunology [CHAVI]; clade B, predominantly males) (9);
high-risk subjects identified with having acute HIV-1 infections
at U.S. sites participating in the Acute Infection and Early
Disease Research Program (AIEDRP; clade B, predominantly
males); acutely infected subjects indentified in Africa by the
Center for the AIDS Programme of Research in South Africa
(CAPRISA; clade C infections, mainly women) (2); subjects
participating in the Zambia-Emory HIV Research Project
(ZEHRP; clade C discordant couple transmission pairs) (3, 6);
early (3 to 6 months) postinfection time points in men enrolled
in the U.S. Multicenter AIDS Cohort Study (MACS) (7); and
women participating in the Women’s Interagency HIV Study
(WIHS) (11).
In collaboration with CHAVI, 87 plasma donor seroconver-
sion panels were evaluated. In these panels, blood draws were
very frequent (every 3 to 5 days), the date of initial PCR-
confirmed infection was available, and viral loads were pro-
vided. The HIV-Selectest was performed as described in detail
in references 4 and 5. Of the 87 CHAVI panels tested, only 45
reached seroconversion (38 males and 7 females) and could be
used for comparison of antibody assay sensitivity. As seen in
Fig. 1A, concordant results from the Abbott third-genera-
tion test and the HIV-Selectest EIA were seen in 18/45
panels (zero difference in detection day for panels 8 to 25).
The Abbott EIA yielded positive results prior to the HIV-
Selectest in 20/45 panels (positive columns for panels 26 to
45). Surprisingly, the HIV-Selectest EIA scored positive
prior to the Abbott test in 7/45 panels (negative columns for
panels 1 to 7). On average, the HIV-Selectest EIA detected
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anti-HIV antibodies 1.6 days (median  0) after the com-
mercial third-generation Abbott EIA.
It was important to expand our survey to include commu-
nity clinic settings. Additional panels of confirmed early
HIV infections in men and women with predominantly clade
B infections were evaluated through collaboration with the
AIEDRP, MACS, and WIHS. The HIV-Selectest EIA sen-
sitivity ranged from 98.7 to 100% and from 93.8 to 98.3% in
men and women, respectively, based on detection of the first
seropositive specimen defined by reference assays in these
studies (Fig. 1B).
Detection of clade C infections was evaluated in the
CAPRISA acute infection and ZEHRP discordant couple
panels from South Africa and Zambia, respectively. The
CAPRISA project was established in South Africa in order to
capture early heterosexual clade C infections and to establish
the rate of viremia and disease progression. Most of the CA-
PRISA participants are women. HIV-1 diagnosis was based on
several rapid tests and EIAs and supplemented by PCR-based
viral load measurements, and acutely infected subjects were
enrolled into a longitudinal follow-up protocol with weekly
specimen collection. Samples tested with the HIV-Selectest
EIA were the first specimens available after confirmed sero-
conversion by the serodiagnostic tests used in the CAPRISA
study (i.e., within 1 to 4 weeks of estimated infection date).
Overall, the HIV-Selectest scored positive no later than 1
sample after seroconversion in 46 panels.
Performance of the HIV-Selectest in capturing clade C in-
FIG. 1. Reactivity of the HIV-Selectest EIA, with samples obtained from acutely HIV-infected males and females. (A) Comparison of
HIV-Selectest EIA performance with that of the Abbott kit during acute viremia (CHAVI panels). HIV-Selectest was performed as described in
references 4 and 5. The difference between the first day of positive reactivity (signal-to-cutoff [S/CO] ratio  1) in the Abbott test (third generation)
and that in the HIV-Selectest EIA was plotted for individual panels. The bars under the horizontal line (zero difference) represent panels in which
the HIV-Selectest EIA scored positive before the Abbott test, while bars above this line represent panels in which the Abbott test scored positive
ahead of the HIV-Selectest EIA. (B) Summary of HIV-Selectest (EIA) reactivity with acutely HIV-infected males and females. HIV-Selectest
shows high sensitivity for detection of HIV-1-infected male and female panels. HIV-Selectest reactivity is considered positive if an S/CO value
of 1 is obtained in either the p6 or the gp41 peptide enzyme-linked immunosorbent assay (ELISA). Fiebig staging has been previously described
(1). No statistical significant difference between males and females was observed (P value  0.68).






























fections was also evaluated in the ZEHRP discordant couple
study. Early seroconversions from 9 female-to-male and 20
male-to-female transmissions were tested. The HIV-Selectest
EIA scored positive with the first HIV infection-confirmed
bleed from 9/9 males and 19/20 females in this panel (Fig. 1B).
Together, the data obtained in the current studies demon-
strated that in spite of the fact that HIV-Selectest EIA is
composed of a limited number of peptides from only two
HIV-1 proteins (gp41 and p6), its sensitivity to detect early
anti-HIV-1 IgG antibodies does not differ significantly from
commercially available rapid tests and third-generation EIAs
used in the HIV screening algorithms in many countries. Over-
FIG. 2. HIV-Selectest rapid test for detection of HIV-1 infections. (A) One positive control protein (goat anti-human IgG; Jackson Immu-
noresearch) and two sets of peptides from HIV-1 gp41 and p6 were striped onto 5-m nitrocellulose membranes (Whatman) at 1 mg/ml per
peptide. One-hundred-fold-diluted serum/plasma samples were allowed to migrate gradually through the membrane and react to HIV peptides,
followed by detection with protein A-coated gold conjugate. Uninfected vaccine recipients were obtained from VRC-009 and VRC-010 (DNA/HIV
prime, adenovirus type 5 [Ad5]/HIV boost). HIV-infected vaccine recipients were obtained from the VaxGen phase III trials in the United States
(clade B) and Thailand (clade E). Clade C samples were obtained from the CAPRISA cohort. (B) Performance of the HIV-Selectest (EIA and
rapid test) using the HIV-1 seroconversion panel (PRB 917; SeraCare BioServices, Inc.). Information on days of collection and results obtained
with the Abbott HIV-1/2-O EIA and 5 FDA-licensed kits (including Abbott HIV-1, Abbott HIV-1/2, GenSys HIV-1, GenSys HIV-1/2, and OraTek
HIV) were provided by SeraCare BioServices. (C) Summary of HIV-Selectest rapid test results with uninfected HIV samples (including HIV
vaccine trial samples) and samples obtained from acutely HIV-infected individuals. HIV-1 clade B samples were obtained from SeraCare
BioServices and NHLBI, clade C samples were obtained from the CAPRISA cohort, and clade E samples were obtained from the VaxGen vaccine
trial VAX-003. HIV-negative samples were obtained from unexposed blood donors and SeraCare BioServices. The HIV vaccine trial samples were
obtained from uninfected vaccine recipients from the HIV vaccine trials VRC-008, VRC-009, and VRC-010.






























all assay sensitivity was found to be 99.1% and 98.1% in early
infection samples obtained from males and females, respec-
tively (Fig. 1B). A two-tailed, unequal sample size, equal vari-
ance t test was performed on the combined HIV-Selectest
reactivity for the HIV-1-positive males and females. Detection
rates were not significantly different between the HIV-infected
men and women, irrespective of the infecting HIV-1 viral
strains (P value  0.68).
Point-of-care rapid testing is potentially of great value to
resource-poor countries. During vaccine trials, a rapid test
could help to capture breakthrough infections, which often
occur between the 3-month scheduled clinic visits. To that end,
we have adapted the HIV-Selectest to a lateral flow test based
on immunochromatographic strip (ICS) technology. As seen in
Fig. 2A, both the p6 and gp41 peptides were reactive with
positive control plasma from SeraCare BioServices (Gaithers-
burg, MD) but not with negative controls obtained from unin-
fected individuals. Importantly, HIV vaccine recipients (Vac-
cine Research Center trials VRC-009 and VRC-010) that were
not infected but gave false-positive results in several commer-
cial HIV rapid tests scored negative in the HIV-Selectest rapid
test, as previously demonstrated with the EIA version (4). On
the other hand, breakthrough infections in HIV vaccine trial
participants (VaxGen phase III trials in the United States
[clade B] and Thailand [clade E]) gave positive reactivity in
the rapid test. Clade C infections (from CAPRISA) also
scored positive in the HIV-Selectest rapid test (Fig. 2A).
In order to compare the sensitivity of the HIV-Selectest
rapid test and EIA with the performance of a third-generation
EIA, we evaluated seroconversion panels from SeraCare Bio-
Services, Inc. In the case of panel PRB 917 (Fig. 2B), the
Abbott HIV-1/2-O test was reactive on day 28, while the HIV-
Selectest EIA and rapid assay (both p6 and gp41) scored pos-
itive as early as day 14, with the bands becoming stronger on
subsequent days (Fig. 2B).
In several proof-of-concept studies conducted with the HIV-
Selectest rapid test, assay specificity is around 99.4% based on
76 seronegative healthy individuals and 81 samples obtained
from HIV-uninfected vaccine trial participants (Fig. 2C, top).
Assay sensitivity is currently in the range of 99.2 to 100% for
confirmed infections with HIV-1 clade B, C, and E viruses (Fig.
2C, bottom), but individual samples may give different patterns
of intensity with the peptide bands, in agreement with what was
found in the EIA version of the HIV-Selectest (4).
The addition of the HIV-Selectest (EIA and rapid test) to
the detection algorithm during ongoing vaccine trials could
facilitate early diagnosis of breakthrough infections and reduce
the number of questionable HIV-seropositive samples that
need nucleic acid testing.
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